Skip to content
Markets News
Stocks1 min read

Lilly’s Foundayo Cuts Sleep Apnea Events in Late-Stage Trial

Makkler Newsroom
November 9, 2026 · Based on reporting by CNBC

The obesity pill reduced apnea events in both trial groups, and Eli Lilly plans to seek U.S. approval by year-end.

Key takeaways

  • Foundayo reduced apnea events in both trial groups at 52 weeks.
  • Eli Lilly plans to file for U.S. approval by the end of 2026.
  • LLY traded at about $1,385, up 2.22% since the previous close as of 14:51 UTC.

Eli Lilly said its obesity pill Foundayo reduced the severity of obstructive sleep apnea in two late-stage studies. The company plans to seek U.S. approval for the treatment in adults with moderate-to-severe sleep apnea and obesity or overweight by the end of the year.

At 52 weeks, participants not using positive airway pressure therapy had an average of 21.1 fewer apnea events per hour with Foundayo, compared with 4.8 fewer with placebo. In the group continuing that therapy, the reductions were 18.3 and 5.5 events per hour, respectively.

Lilly said side-effect data were generally consistent with previous trials, with gastrointestinal issues among the most common effects. As of 14:51 UTC, Lilly shares traded at about $1,385, up 2.22% since the previous close.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.